{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Foncologypodcast.simplecast.com%2Fepisodes%2Fcdk4-6-inhibitors-for-breast-cancer-QkfLaidR","width":444,"version":"1.0","type":"rich","title":"Expert Insights and FAQs on CDK4/6 Inhibitors in the Care of Today’s Patients With HR-Positive/HER2-Negative Breast Cancer","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/26d7523c-7315-48a0-9da6-29d252d3ce90/55f431b9-e524-42a3-a56c-487ee3ce88d9/9235-pod-cdk4-6-inhibitors-for-breast-cancer.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"<iframe src=\"https://player.simplecast.com/afa687ed-a5cb-488b-b8c0-9c7598c3d3bc\" height=\"200\" width=\"100%\" title=\"Expert Insights and FAQs on CDK4/6 Inhibitors in the Care of Today’s Patients With HR-Positive/HER2-Negative Breast Cancer\" frameborder=\"0\" scrolling=\"no\"></iframe>","height":200,"description":"Listen as experts discuss key clinical pearls and answer frequently asked questions on the use of CDK4/6 inhibitors for HR-positive/HER2-negative early and metastatic breast cancer in this podcast episode, including insights related to optimal sequencing and ensuring adherence to therapy."}